Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.
A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX). Skin rash involved regions of the face, lower abdomen, back, buttocks and both upper thighs. Biopsy of the skin rash demonstrated superficial perivascular lymphocytic infiltrate and was consistent with a drug reaction. Peripheral blood count revealed pancytopenia and a bone marrow biopsy was consistent with aplasia. Blood counts returned to normal 6 days after institution of granulocyte colony stimulating factor therapy. In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to MTX in this patient. Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life-threatening bone marrow aplasia.
Copur
S
S
NCI-Navy Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20889-5105, USA.
Dahut
W
W
Chu
E
E
Allegra
C J
CJ
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D003875:Drug Eruptions / Q000209:etiology*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced* / Q000628:therapy
D007155:Immunologic Factors; D016179:Granulocyte Colony-Stimulating Factor; D008727:Methotrexate